Table of Contents
Lung Cancer International
Volume 2014, Article ID 731925, 10 pages
http://dx.doi.org/10.1155/2014/731925
Research Article

Simple and Objective Prediction of Survival in Patients with Lung Cancer: Staging the Host Systemic Inflammatory Response

1Beatson Oncology Centre, 1053 Great Western Road, Glasgow G12 0YN, UK
2University of Aberdeen, Aberdeen, UK
3Inverclyde Royal Hospital, Inverclyde, UK
4Queen Margaret Hospital, Dunfermline, UK
5University of Glasgow, Glasgow, UK
6Glasgow Royal Infirmary, Glasgow, UK
7Aberdeen Royal Infirmary, Aberdeen, UK

Received 27 August 2013; Revised 20 December 2013; Accepted 24 December 2013; Published 5 March 2014

Academic Editor: Seiji Niho

Copyright © 2014 Derek Grose et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. F. Berrino, R. De Angelis, M. Sant et al., “Survival for eight major cancers and all cancers combined for European adults diagnosed in 1995–99: results of the EUROCARE-4 study,” Lancet Oncology, vol. 8, no. 9, pp. 773–783, 2007. View at Publisher · View at Google Scholar · View at Scopus
  2. M. L. G. Janssen-Heijnen, G. Gatta, D. Forman, R. Capocaccia, and J. W. W. Coebergh, “Variation in survival of patients with lung cancer in Europe, 1985–1989,” European Journal of Cancer, vol. 34, no. 14, pp. 2191–2196, 1998. View at Publisher · View at Google Scholar · View at Scopus
  3. M. Maltoni, A. Caraceni, C. Brunelli et al., “Prognostic factors in advanced cancer patients: evidence-based clinical recommendations—a study by the steering committee of the european association for palliative care,” Journal of Clinical Oncology, vol. 23, no. 25, pp. 6240–6248, 2005. View at Publisher · View at Google Scholar · View at Scopus
  4. L. Martin, S. Watanabe, R. Fainsinger et al., “Prognostic factors in patients with advanced cancer: use of the patient-generated subjective global assessment in survival prediction,” Journal of Clinical Oncology, vol. 28, no. 28, pp. 4376–4383, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. P. A. Glare, S. Eychmueller, and P. McMahon, “Diagnostic accuracy of the Palliative Prognostic score in hospitalized patients with advanced cancer,” Journal of Clinical Oncology, vol. 22, no. 23, pp. 4823–4828, 2004. View at Publisher · View at Google Scholar · View at Scopus
  6. S. Gripp, S. Moeller, E. Bölke et al., “Survival prediction in terminally ill cancer patients by clinical estimates, laboratory tests, and self-rated anxiety and depression,” Journal of Clinical Oncology, vol. 25, no. 22, pp. 3313–3320, 2007. View at Publisher · View at Google Scholar · View at Scopus
  7. D. C. McMillan, “Systemic inflammation, nutritional status and survival in patients with cancer,” Current Opinion in Clinical Nutrition and Metabolic Care, vol. 12, no. 3, pp. 223–226, 2009. View at Publisher · View at Google Scholar · View at Scopus
  8. M. J. Proctor, D. S. Morrison, D. Talwar et al., “An inflammation-based prognostic score (mGPS) predicts cancer survival independent of tumour site: a Glasgow Inflammation Outcome Study,” British Journal of Cancer, vol. 104, no. 4, pp. 726–734, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. S. Wilop, M. Crysandt, M. Bendel, A. H. Mahnken, R. Osieka, and E. Jost, “Correlation of C-reactive protein with survival and radiographic response to first-line platinum-based chemotherapy in advanced non-small cell lung cancer,” Onkologie, vol. 31, no. 12, pp. 665–670, 2008. View at Publisher · View at Google Scholar · View at Scopus
  10. A. Koch, H. Fohlin, and S. Sörenson, “Prognostic significance of C-reactive protein and smoking in patients with advanced non-small cell lung cancer treated with first-line palliative chemotherapy,” Journal of Thoracic Oncology, vol. 4, no. 3, pp. 326–332, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. B. Gagnon, M. Abrahamowicz, Y. Xiao et al., “Flexible modeling improves assessment of prognostic value of C-reactive protein in advanced non-small cell lung cancer,” British Journal of Cancer, vol. 102, no. 7, pp. 1113–1122, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. O. Arrieta, R. M. Michel Ortega, G. Villanueva-Rodríguez et al., “Association of nutritional status and serum albumin levels with development of toxicity in patients with advanced non-small cell lung cancer treated with paclitaxel-cisplatin chemotherapy: a prospective study,” BMC Cancer, vol. 10, article 50, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. L. M. Forrest, D. C. McMillan, C. S. McArdle, W. J. Angerson, and D. J. Dunlop, “Comparison of an inflammation-based prognostic score (GPS) with performance status (ECOG) in patients receiving platinum-based chemotherapy for inoperable non-small-cell lung cancer,” British Journal of Cancer, vol. 90, no. 9, pp. 1704–1706, 2004. View at Google Scholar · View at Scopus
  14. L. M. Forrest, D. C. McMillan, C. S. McArdle, W. J. Angerson, K. Dagg, and H. R. Scott, “A prospective longitudinal study of performance status, an inflammation-based score (GPS) and survival in patients with inoperable non-small-cell lung cancer,” British Journal of Cancer, vol. 92, no. 10, pp. 1834–1836, 2005. View at Publisher · View at Google Scholar · View at Scopus
  15. D. J. F. Brown, R. Milroy, T. Preston, and D. C. McMillan, “The relationship between an inflammation-based prognostic score (Glasgow Prognostic Score) and changes in serum biochemical variables in patients with advanced lung and gastrointestinal cancer,” Journal of Clinical Pathology, vol. 60, no. 6, pp. 705–708, 2007. View at Publisher · View at Google Scholar · View at Scopus
  16. E. Y. L. Leung, H. R. Scott, and D. C. McMillan, “Clinical utility of the pretreatment glasgow prognostic score in patients with advanced inoperable non-small cell lung cancer,” Journal of Thoracic Oncology, vol. 7, no. 4, pp. 655–662, 2012. View at Publisher · View at Google Scholar · View at Scopus
  17. D. C. McMillan, “The systemic inflammation-based Glasgow Prognostic Score: a decade of experience in patients with cancer,” Cancer Treatment Reviews, vol. 39, no. 5, pp. 534–540, 2013. View at Publisher · View at Google Scholar
  18. Scottish Intercollegiate Guidelines Network (SIGN), Management of Patients with Lung Cancer, 2005, http://www.sign.ac.uk/pdf/sign80.pdf.
  19. D. Grose, G. Devereux, L. Brown et al., “Variation in comorbidity and clinical management in patients newly diagnosed with lung cancer in four Scottish centers,” Journal of Thoracic Oncology, vol. 6, no. 3, pp. 500–509, 2011. View at Publisher · View at Google Scholar · View at Scopus
  20. Office of the Chief Statistician and Scottish Executive, “Scottish Index of Multiple Deprivation 2006,” Tech. Rep., http://www.scotland.gov.uk/Publications/2006/10/13142913/0.
  21. L. M. Forrest, D. C. McMillan, C. S. McArdle, W. J. Angerson, and D. J. Dunlop, “Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer,” British Journal of Cancer, vol. 89, no. 6, pp. 1028–1030, 2003. View at Publisher · View at Google Scholar · View at Scopus
  22. D. C. McMillan, J. E. M. Crozier, K. Canna, W. J. Angerson, and C. S. McArdle, “Evaluation of an inflammation-based prognostic score (GPS) in patients undergoing resection for colon and rectal cancer,” International Journal of Colorectal Disease, vol. 22, no. 8, pp. 881–886, 2007. View at Publisher · View at Google Scholar · View at Scopus
  23. A. B. C. Crumley, R. C. Stuart, M. McKernan, A. C. McDonald, and D. C. McMillan, “Comparison of an inflammation-based prognostic score (GPS) with performance status (ECOG-ps) in patients receiving palliative chemotherapy for gastroesophageal cancer,” Journal of Gastroenterology and Hepatology, vol. 23, no. 8, pp. e325–e329, 2008. View at Publisher · View at Google Scholar · View at Scopus
  24. A. L. Rich, L. J. Tata, R. A. Stanley et al., “Lung cancer in England: information from the National Lung Cancer Audit (LUCADA),” Lung Cancer, vol. 72, no. 1, pp. 16–22, 2011. View at Publisher · View at Google Scholar · View at Scopus
  25. N. MacDonald, “Terminology in cancer cachexia: importance and status,” Current Opinion in Clinical Nutrition and Metabolic Care, vol. 15, no. 3, pp. 220–225, 2012. View at Publisher · View at Google Scholar · View at Scopus
  26. G. V. Scagliotti, P. Parikh, J. Von Pawel et al., “Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer,” Journal of Clinical Oncology, vol. 26, no. 21, pp. 3543–3551, 2008. View at Publisher · View at Google Scholar · View at Scopus
  27. T. W. Du Clos and C. Mold, “C-reactive protein: an activator of innate immunity and a modulator of adaptive immunity,” Immunologic Research, vol. 30, no. 3, pp. 261–277, 2004. View at Publisher · View at Google Scholar · View at Scopus
  28. T. Nozoe, T. Matsumata, and K. Sugimachi, “Preoperative elevation of serum C-reactive protein is related to impaired immunity in patients with colorectal cancer,” American Journal of Clinical Oncology, vol. 23, no. 3, pp. 263–266, 2000. View at Publisher · View at Google Scholar · View at Scopus
  29. L. M. Coussens and Z. Werb, “Inflammation and cancer,” Nature, vol. 420, no. 6917, pp. 860–867, 2002. View at Publisher · View at Google Scholar · View at Scopus
  30. R. Abramovitch, M. Marikovsky, G. Meir, and M. Neeman, “Stimulation of tumour growth by wound-derived growth factors,” British Journal of Cancer, vol. 79, no. 9-10, pp. 1392–1398, 1999. View at Google Scholar · View at Scopus
  31. K. Canna, M. Hilmy, D. C. Mcmillan et al., “The relationship between tumour proliferative activity, the systemic inflammatory response and survival in patients undergoing curative resection for colorectal cancer,” Colorectal Disease, vol. 10, no. 7, pp. 663–667, 2008. View at Publisher · View at Google Scholar · View at Scopus
  32. S. B. Edge, D. R. Bird, and C. C. Compton, AJCC Cancer Staging Manual, 7th edition, 2009.
  33. B. J. Laird, S. Kaasa, D. C. McMillan et al., “Prognostic factors in patients with advanced cancer: a comparison of clinicopathological factors and the development of an inflammation-based prognostic system,” Clinical Cancer Research, vol. 19, pp. 5456–5464, 2013. View at Google Scholar